Recurrent Primary Mediastinal Large B-Cell Lymphoma Clinical Trials

8 clinical trials for Recurrent Primary Mediastinal Large B-Cell Lymphoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma — RECRUITING · PHASE1
• Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T — RECRUITING · PHASE2
• Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE2
• Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy — RECRUITING · PHASE2
• Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas — ACTIVE_NOT_RECRUITING · PHASE2
• NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma — COMPLETED · PHASE2

Refine this search